Perspectives
perspectives
August 17th, 2026
From Signal to System: The Evidence Questions Psychedelic Therapies Must Answer
perspectives
August 11th, 2026
The Race to Faster Drug Development: A Quicker On-Ramp Doesn’t Help If You’re Headed the Wrong Way
perspectives
August 7th, 2026
UK Clinical Trial Transparency Changes for Phase I Studies: What Sponsors Need to Know
perspectives
July 31st, 2026
FDA Orphan Drug Designation Requirements: Key Mistakes to Avoid
perspectives
July 29th, 2026
From Signal to System: The Next Challenges for Psychedelic Therapies
perspectives
July 24th, 2026
FDA’s Latest Psychedelic Guidance: Key Changes and Implications for Sponsors
perspectives
July 7th, 2026
Don’t Veer for Deer: Why Drug Development Needs Steady Steering in the Age of AI and Real-Time Data
perspectives
July 6th, 2026
How REMS Defines the Patient Journey in Psychedelic Therapies
perspectives
June 30th, 2026
The Future of Biostatistics: Insights from Presenters at PSI 2026
perspectives
June 11th, 2026
AI in Regulatory Strategy: Practical Uses for Submission Readiness
perspectives
June 3rd, 2026
What Pharma Can Learn from Data Science Outside the Industry
perspectives
May 19th, 2026
Turning Real-World Data into Reliable Evidence: The Role of Data Science